Janet Snell-Bergeon
Concepts (467)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 157 | 2023 | 3388 | 16.360 |
Why?
| Coronary Artery Disease | 42 | 2023 | 695 | 8.810 |
Why?
| Vascular Calcification | 19 | 2023 | 124 | 7.500 |
Why?
| Diabetic Nephropathies | 25 | 2022 | 292 | 5.670 |
Why?
| Diabetic Angiopathies | 29 | 2020 | 270 | 5.510 |
Why?
| Insulin Resistance | 26 | 2024 | 1192 | 4.430 |
Why?
| Blood Glucose | 42 | 2024 | 1957 | 3.410 |
Why?
| Calcinosis | 23 | 2021 | 292 | 2.990 |
Why?
| Coronary Vessels | 14 | 2023 | 237 | 2.810 |
Why?
| Albuminuria | 15 | 2022 | 195 | 2.710 |
Why?
| Blood Glucose Self-Monitoring | 22 | 2023 | 531 | 2.530 |
Why?
| Adult | 132 | 2023 | 32385 | 2.330 |
Why?
| Cardiovascular Diseases | 19 | 2024 | 1859 | 2.210 |
Why?
| Diabetes Complications | 9 | 2019 | 226 | 2.060 |
Why?
| Risk Factors | 53 | 2023 | 9381 | 1.800 |
Why?
| Hypoglycemia | 7 | 2023 | 406 | 1.770 |
Why?
| Middle Aged | 101 | 2023 | 28563 | 1.750 |
Why?
| Biomarkers | 24 | 2022 | 3662 | 1.710 |
Why?
| Osteoporotic Fractures | 5 | 2020 | 52 | 1.620 |
Why?
| Diabetes Mellitus, Type 2 | 16 | 2024 | 2221 | 1.600 |
Why?
| Glomerular Filtration Rate | 22 | 2022 | 697 | 1.560 |
Why?
| Humans | 180 | 2024 | 122796 | 1.520 |
Why?
| Disease Progression | 34 | 2023 | 2546 | 1.510 |
Why?
| Uric Acid | 8 | 2018 | 354 | 1.510 |
Why?
| Female | 136 | 2023 | 63629 | 1.500 |
Why?
| Atherosclerosis | 8 | 2022 | 354 | 1.470 |
Why?
| Male | 126 | 2023 | 59639 | 1.400 |
Why?
| Young Adult | 54 | 2023 | 11094 | 1.370 |
Why?
| Insulin | 23 | 2023 | 2180 | 1.340 |
Why?
| Pregnancy in Diabetics | 2 | 2020 | 89 | 1.330 |
Why?
| Coronary Disease | 9 | 2015 | 372 | 1.310 |
Why?
| Glycopeptides | 3 | 2018 | 58 | 1.310 |
Why?
| Prospective Studies | 27 | 2023 | 6704 | 1.200 |
Why?
| Hypoglycemic Agents | 16 | 2023 | 1055 | 1.150 |
Why?
| Diet, Mediterranean | 2 | 2023 | 21 | 1.110 |
Why?
| Cohort Studies | 32 | 2023 | 5294 | 1.110 |
Why?
| Calcium | 11 | 2023 | 1244 | 1.080 |
Why?
| Cross-Sectional Studies | 28 | 2023 | 4734 | 1.060 |
Why?
| Case-Control Studies | 27 | 2022 | 3296 | 0.990 |
Why?
| Insulin Infusion Systems | 7 | 2022 | 305 | 0.970 |
Why?
| Hyperglycemia | 7 | 2022 | 326 | 0.950 |
Why?
| Cactaceae | 1 | 2023 | 6 | 0.930 |
Why?
| Dietary Fiber | 2 | 2023 | 46 | 0.910 |
Why?
| Longitudinal Studies | 11 | 2021 | 2599 | 0.900 |
Why?
| Inflammation | 5 | 2021 | 2598 | 0.890 |
Why?
| Follow-Up Studies | 14 | 2023 | 4768 | 0.830 |
Why?
| Trace Elements | 1 | 2022 | 50 | 0.830 |
Why?
| Triglycerides | 10 | 2020 | 527 | 0.820 |
Why?
| Diabetic Cardiomyopathies | 2 | 2019 | 40 | 0.820 |
Why?
| Adiponectin | 6 | 2016 | 231 | 0.800 |
Why?
| Obesity | 11 | 2023 | 2786 | 0.800 |
Why?
| Prediabetic State | 2 | 2023 | 236 | 0.800 |
Why?
| Diabetic Retinopathy | 4 | 2017 | 156 | 0.750 |
Why?
| Cystatin C | 8 | 2015 | 71 | 0.730 |
Why?
| Bone Density | 7 | 2022 | 451 | 0.720 |
Why?
| Vascular Stiffness | 4 | 2022 | 429 | 0.720 |
Why?
| Body Mass Index | 15 | 2021 | 2144 | 0.710 |
Why?
| Osteoporosis, Postmenopausal | 1 | 2019 | 38 | 0.680 |
Why?
| Uromodulin | 1 | 2018 | 28 | 0.670 |
Why?
| Proteomics | 7 | 2022 | 890 | 0.670 |
Why?
| Apolipoproteins B | 2 | 2015 | 44 | 0.660 |
Why?
| Cholesterol, HDL | 6 | 2022 | 202 | 0.650 |
Why?
| Cancellous Bone | 1 | 2017 | 22 | 0.640 |
Why?
| Islets of Langerhans | 2 | 2022 | 749 | 0.630 |
Why?
| Pericardium | 2 | 2017 | 53 | 0.630 |
Why?
| Diet | 3 | 2023 | 1168 | 0.620 |
Why?
| Kidney | 6 | 2021 | 1355 | 0.620 |
Why?
| Body Fat Distribution | 1 | 2017 | 46 | 0.610 |
Why?
| Metabolic Syndrome | 1 | 2021 | 395 | 0.600 |
Why?
| Kidney Function Tests | 3 | 2020 | 166 | 0.600 |
Why?
| Feeding Behavior | 2 | 2021 | 627 | 0.590 |
Why?
| Fear | 1 | 2019 | 313 | 0.590 |
Why?
| Subcutaneous Fat | 1 | 2017 | 86 | 0.580 |
Why?
| Adiposity | 6 | 2023 | 523 | 0.580 |
Why?
| Adolescent | 34 | 2023 | 18948 | 0.580 |
Why?
| Kidney Diseases | 2 | 2012 | 446 | 0.580 |
Why?
| Menopause | 1 | 2019 | 270 | 0.570 |
Why?
| Logistic Models | 12 | 2015 | 1995 | 0.570 |
Why?
| Femur Neck | 4 | 2022 | 65 | 0.570 |
Why?
| Glucagon-Like Peptide 1 | 3 | 2022 | 105 | 0.560 |
Why?
| Exercise | 4 | 2023 | 1743 | 0.550 |
Why?
| Tomography, X-Ray Computed | 14 | 2019 | 2500 | 0.550 |
Why?
| Perception | 1 | 2018 | 324 | 0.540 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2013 | 44 | 0.530 |
Why?
| Energy Intake | 4 | 2023 | 453 | 0.530 |
Why?
| Pyrazines | 2 | 2013 | 79 | 0.530 |
Why?
| Autoimmunity | 3 | 2022 | 852 | 0.520 |
Why?
| Brachial Artery | 1 | 2016 | 183 | 0.510 |
Why?
| Triazoles | 2 | 2013 | 135 | 0.500 |
Why?
| Dietary Fats | 3 | 2021 | 325 | 0.500 |
Why?
| Renal Insufficiency | 1 | 2016 | 154 | 0.490 |
Why?
| Fractures, Bone | 1 | 2019 | 378 | 0.490 |
Why?
| Fibrinogen | 4 | 2023 | 162 | 0.480 |
Why?
| Self Report | 1 | 2018 | 730 | 0.480 |
Why?
| Renal Insufficiency, Chronic | 5 | 2021 | 602 | 0.480 |
Why?
| Pilot Projects | 10 | 2021 | 1477 | 0.480 |
Why?
| Menarche | 2 | 2011 | 51 | 0.470 |
Why?
| Metformin | 1 | 2017 | 303 | 0.470 |
Why?
| Up-Regulation | 2 | 2016 | 891 | 0.470 |
Why?
| Patient Care Planning | 1 | 2014 | 143 | 0.460 |
Why?
| Postprandial Period | 2 | 2013 | 99 | 0.450 |
Why?
| Prognosis | 8 | 2018 | 3563 | 0.440 |
Why?
| Glucagon | 1 | 2013 | 97 | 0.440 |
Why?
| Models, Theoretical | 2 | 2015 | 574 | 0.420 |
Why?
| Predictive Value of Tests | 12 | 2020 | 1947 | 0.410 |
Why?
| Ketosis | 2 | 2022 | 13 | 0.410 |
Why?
| Pancreas, Artificial | 2 | 2023 | 71 | 0.410 |
Why?
| Lipids | 5 | 2022 | 614 | 0.410 |
Why?
| Patient Satisfaction | 1 | 2015 | 632 | 0.400 |
Why?
| Cholesterol | 6 | 2014 | 380 | 0.400 |
Why?
| Aged | 19 | 2021 | 20495 | 0.390 |
Why?
| Incidence | 6 | 2021 | 2527 | 0.390 |
Why?
| Evidence-Based Medicine | 2 | 2012 | 731 | 0.390 |
Why?
| Child | 23 | 2022 | 19561 | 0.390 |
Why?
| Age Factors | 11 | 2020 | 3114 | 0.380 |
Why?
| Proteinuria | 2 | 2010 | 98 | 0.360 |
Why?
| Haptoglobins | 3 | 2015 | 30 | 0.360 |
Why?
| Colorado | 9 | 2016 | 4325 | 0.350 |
Why?
| Periodontal Diseases | 2 | 2023 | 58 | 0.350 |
Why?
| Adipose Tissue | 4 | 2018 | 616 | 0.350 |
Why?
| Diabetic Ketoacidosis | 2 | 2022 | 173 | 0.350 |
Why?
| Prevalence | 11 | 2023 | 2442 | 0.340 |
Why?
| Self-Management | 2 | 2023 | 136 | 0.340 |
Why?
| Diet, Ketogenic | 1 | 2009 | 32 | 0.340 |
Why?
| Creatinine | 9 | 2022 | 510 | 0.340 |
Why?
| Aging | 1 | 2019 | 1694 | 0.340 |
Why?
| Reproductive History | 1 | 2008 | 12 | 0.330 |
Why?
| Collagen | 1 | 2010 | 436 | 0.320 |
Why?
| Glucose Clamp Technique | 8 | 2018 | 195 | 0.320 |
Why?
| Sex Factors | 8 | 2020 | 1860 | 0.320 |
Why?
| Blood Pressure | 9 | 2017 | 1713 | 0.320 |
Why?
| Vitamins | 2 | 2022 | 163 | 0.320 |
Why?
| Time Factors | 8 | 2018 | 6682 | 0.310 |
Why?
| Muscle, Skeletal | 4 | 2020 | 1556 | 0.310 |
Why?
| Genome-Wide Association Study | 3 | 2019 | 1376 | 0.310 |
Why?
| Absorptiometry, Photon | 5 | 2022 | 230 | 0.310 |
Why?
| Lumbar Vertebrae | 3 | 2020 | 217 | 0.310 |
Why?
| Osteoporosis | 3 | 2020 | 234 | 0.300 |
Why?
| C-Reactive Protein | 3 | 2023 | 363 | 0.300 |
Why?
| Lipoproteins, HDL | 2 | 2019 | 82 | 0.300 |
Why?
| Anthropometry | 3 | 2017 | 200 | 0.300 |
Why?
| Heart Rate | 1 | 2010 | 756 | 0.290 |
Why?
| Surveys and Questionnaires | 7 | 2021 | 4882 | 0.290 |
Why?
| Contraception | 1 | 2008 | 123 | 0.280 |
Why?
| Diabetes Mellitus, Experimental | 3 | 2019 | 213 | 0.270 |
Why?
| Early Diagnosis | 2 | 2017 | 242 | 0.270 |
Why?
| Retrospective Studies | 8 | 2021 | 13433 | 0.260 |
Why?
| Multivariate Analysis | 5 | 2015 | 1531 | 0.260 |
Why?
| Abdominal Wall | 1 | 2004 | 27 | 0.260 |
Why?
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 21 | 0.240 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2023 | 84 | 0.230 |
Why?
| Fast Foods | 1 | 2023 | 16 | 0.230 |
Why?
| Amino Acids, Branched-Chain | 1 | 2023 | 32 | 0.230 |
Why?
| Cholesterol, LDL | 3 | 2015 | 326 | 0.230 |
Why?
| Food Handling | 1 | 2023 | 51 | 0.230 |
Why?
| Calcium, Dietary | 1 | 2023 | 55 | 0.230 |
Why?
| Pregnancy | 6 | 2021 | 5854 | 0.230 |
Why?
| Sweetening Agents | 1 | 2023 | 53 | 0.230 |
Why?
| Periodontitis | 1 | 2023 | 42 | 0.220 |
Why?
| Risk Assessment | 6 | 2020 | 3213 | 0.220 |
Why?
| Plaque, Atherosclerotic | 2 | 2014 | 45 | 0.220 |
Why?
| Pulmonary Surfactant-Associated Protein B | 1 | 2022 | 7 | 0.220 |
Why?
| Glucose Intolerance | 1 | 2024 | 140 | 0.220 |
Why?
| Lipoproteins | 2 | 2016 | 164 | 0.220 |
Why?
| Manganese | 1 | 2022 | 57 | 0.210 |
Why?
| Polymorphism, Genetic | 5 | 2011 | 666 | 0.210 |
Why?
| Benchmarking | 1 | 2023 | 184 | 0.210 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 152 | 0.210 |
Why?
| Insulins | 1 | 2022 | 35 | 0.210 |
Why?
| Copper | 1 | 2022 | 101 | 0.210 |
Why?
| Diglycerides | 2 | 2020 | 60 | 0.210 |
Why?
| Mass Spectrometry | 4 | 2017 | 686 | 0.200 |
Why?
| Peptides | 3 | 2017 | 893 | 0.200 |
Why?
| Inflammasomes | 1 | 2023 | 123 | 0.200 |
Why?
| Diet Surveys | 1 | 2021 | 86 | 0.200 |
Why?
| Intra-Abdominal Fat | 3 | 2017 | 98 | 0.200 |
Why?
| Automobile Driving | 1 | 2023 | 129 | 0.200 |
Why?
| Insulin, Long-Acting | 1 | 2021 | 49 | 0.200 |
Why?
| Beverages | 1 | 2021 | 70 | 0.200 |
Why?
| Pregnancy Outcome | 2 | 2021 | 364 | 0.200 |
Why?
| Regression Analysis | 7 | 2014 | 1018 | 0.190 |
Why?
| Dyslipidemias | 3 | 2015 | 165 | 0.190 |
Why?
| Meat | 1 | 2021 | 93 | 0.190 |
Why?
| Proteome | 2 | 2017 | 357 | 0.190 |
Why?
| Diabetes Mellitus | 1 | 2009 | 985 | 0.190 |
Why?
| Blindness | 1 | 2020 | 35 | 0.190 |
Why?
| Genotype | 7 | 2018 | 1943 | 0.190 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 839 | 0.190 |
Why?
| Vitamin D Deficiency | 2 | 2013 | 167 | 0.180 |
Why?
| Fruit | 1 | 2021 | 134 | 0.180 |
Why?
| Double-Blind Method | 5 | 2022 | 1711 | 0.180 |
Why?
| Glomerular Basement Membrane | 1 | 2019 | 7 | 0.180 |
Why?
| Foam Cells | 1 | 2019 | 16 | 0.180 |
Why?
| Collagen Type IV | 1 | 2019 | 22 | 0.180 |
Why?
| Reproducibility of Results | 4 | 2018 | 2977 | 0.180 |
Why?
| Hip Fractures | 1 | 2020 | 84 | 0.170 |
Why?
| Bone Development | 1 | 2019 | 55 | 0.170 |
Why?
| Premenopause | 1 | 2019 | 109 | 0.170 |
Why?
| Radius | 1 | 2019 | 31 | 0.170 |
Why?
| Diet Records | 1 | 2019 | 81 | 0.170 |
Why?
| Severity of Illness Index | 3 | 2016 | 2784 | 0.170 |
Why?
| Polycystic Ovary Syndrome | 1 | 2021 | 158 | 0.170 |
Why?
| Waist Circumference | 2 | 2015 | 132 | 0.170 |
Why?
| Bone Diseases, Metabolic | 1 | 2019 | 60 | 0.160 |
Why?
| Weight Gain | 2 | 2019 | 511 | 0.160 |
Why?
| Sex Distribution | 3 | 2010 | 370 | 0.160 |
Why?
| Antioxidants | 1 | 2022 | 581 | 0.160 |
Why?
| Sodium Bicarbonate | 1 | 2018 | 51 | 0.160 |
Why?
| Depressive Disorder, Major | 1 | 2021 | 309 | 0.160 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 2018 | 75 | 0.160 |
Why?
| Accelerometry | 1 | 2018 | 83 | 0.160 |
Why?
| Obesity, Abdominal | 1 | 2017 | 39 | 0.160 |
Why?
| United States | 6 | 2023 | 13272 | 0.160 |
Why?
| Coronary Angiography | 2 | 2014 | 336 | 0.160 |
Why?
| Depression | 2 | 2021 | 1190 | 0.150 |
Why?
| Tomography Scanners, X-Ray Computed | 1 | 2017 | 18 | 0.150 |
Why?
| Linear Models | 4 | 2014 | 854 | 0.150 |
Why?
| Sphingolipids | 1 | 2018 | 63 | 0.150 |
Why?
| Sex Characteristics | 4 | 2018 | 690 | 0.150 |
Why?
| Tibia | 1 | 2019 | 182 | 0.150 |
Why?
| Hyperlipidemias | 2 | 2011 | 134 | 0.150 |
Why?
| Retinal Vessels | 1 | 2017 | 53 | 0.150 |
Why?
| Self Care | 2 | 2018 | 360 | 0.150 |
Why?
| C-Peptide | 1 | 2018 | 137 | 0.150 |
Why?
| Cross-Over Studies | 4 | 2022 | 469 | 0.150 |
Why?
| Random Allocation | 1 | 2018 | 360 | 0.150 |
Why?
| Albumins | 2 | 2016 | 104 | 0.150 |
Why?
| Dietary Supplements | 2 | 2018 | 473 | 0.150 |
Why?
| Sleep Deprivation | 1 | 2019 | 174 | 0.140 |
Why?
| Histocompatibility Antigens Class I | 1 | 2018 | 176 | 0.140 |
Why?
| Autoantigens | 1 | 2019 | 407 | 0.140 |
Why?
| Vascular Capacitance | 1 | 2016 | 4 | 0.140 |
Why?
| Autoantibodies | 2 | 2022 | 1353 | 0.140 |
Why?
| Hip Joint | 1 | 2017 | 147 | 0.140 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2016 | 12 | 0.140 |
Why?
| Sitagliptin Phosphate | 2 | 2013 | 27 | 0.140 |
Why?
| Electrophoresis, Capillary | 2 | 2017 | 22 | 0.140 |
Why?
| Pulse Wave Analysis | 3 | 2023 | 216 | 0.130 |
Why?
| Hypertension | 5 | 2015 | 1245 | 0.130 |
Why?
| Circadian Rhythm | 1 | 2019 | 414 | 0.130 |
Why?
| Cannabis | 1 | 2022 | 389 | 0.130 |
Why?
| Observational Studies as Topic | 1 | 2015 | 91 | 0.130 |
Why?
| Vitamin E | 1 | 2015 | 119 | 0.130 |
Why?
| Software | 1 | 2019 | 631 | 0.130 |
Why?
| Apolipoproteins | 1 | 2014 | 40 | 0.130 |
Why?
| Peptidomimetics | 1 | 2014 | 2 | 0.120 |
Why?
| Achievement | 1 | 2014 | 56 | 0.120 |
Why?
| Breakfast | 1 | 2014 | 18 | 0.120 |
Why?
| Liver | 4 | 2015 | 1827 | 0.120 |
Why?
| Hemodynamics | 1 | 2018 | 1036 | 0.120 |
Why?
| Fructose | 1 | 2015 | 204 | 0.120 |
Why?
| Goals | 1 | 2015 | 167 | 0.120 |
Why?
| Acute Coronary Syndrome | 1 | 2017 | 268 | 0.120 |
Why?
| Motor Activity | 1 | 2018 | 679 | 0.110 |
Why?
| HLA-DR2 Antigen | 1 | 2012 | 8 | 0.110 |
Why?
| Risk | 1 | 2016 | 890 | 0.110 |
Why?
| Chromatography, Liquid | 2 | 2012 | 356 | 0.110 |
Why?
| Bromocriptine | 2 | 2022 | 28 | 0.110 |
Why?
| Sleep | 1 | 2019 | 722 | 0.110 |
Why?
| Fatty Acids, Monounsaturated | 1 | 2012 | 48 | 0.110 |
Why?
| Fasting | 1 | 2014 | 266 | 0.110 |
Why?
| Neovascularization, Pathologic | 2 | 2011 | 292 | 0.110 |
Why?
| HLA-DQ beta-Chains | 1 | 2012 | 62 | 0.110 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 432 | 0.110 |
Why?
| HLA-DRB1 Chains | 1 | 2012 | 98 | 0.110 |
Why?
| Quality of Life | 1 | 2023 | 2457 | 0.110 |
Why?
| Apolipoprotein C-III | 2 | 2023 | 13 | 0.100 |
Why?
| Early Medical Intervention | 1 | 2012 | 56 | 0.100 |
Why?
| Models, Statistical | 1 | 2015 | 651 | 0.100 |
Why?
| Animals | 9 | 2022 | 34133 | 0.100 |
Why?
| Puberty, Delayed | 1 | 2011 | 5 | 0.100 |
Why?
| Menstruation Disturbances | 1 | 2011 | 12 | 0.100 |
Why?
| Allylamine | 1 | 2011 | 7 | 0.100 |
Why?
| Mutation | 2 | 2019 | 3493 | 0.100 |
Why?
| Adipocytes | 1 | 2012 | 201 | 0.100 |
Why?
| Angiopoietin-1 | 1 | 2010 | 11 | 0.100 |
Why?
| Angiopoietin-2 | 1 | 2010 | 13 | 0.100 |
Why?
| ROC Curve | 3 | 2020 | 494 | 0.100 |
Why?
| Matrix Metalloproteinases | 1 | 2011 | 91 | 0.100 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2010 | 68 | 0.100 |
Why?
| Aged, 80 and over | 3 | 2018 | 6845 | 0.100 |
Why?
| Gastrointestinal Diseases | 1 | 2012 | 195 | 0.100 |
Why?
| Observer Variation | 1 | 2011 | 314 | 0.090 |
Why?
| Cardiovascular System | 1 | 2012 | 132 | 0.090 |
Why?
| Pregnant Women | 2 | 2021 | 137 | 0.090 |
Why?
| Guideline Adherence | 1 | 2015 | 560 | 0.090 |
Why?
| Vitamin D | 1 | 2013 | 363 | 0.090 |
Why?
| Patient Education as Topic | 2 | 2005 | 717 | 0.090 |
Why?
| Hypolipidemic Agents | 1 | 2010 | 88 | 0.090 |
Why?
| Glucose Tolerance Test | 2 | 2024 | 370 | 0.090 |
Why?
| Models, Biological | 3 | 2015 | 1756 | 0.090 |
Why?
| Treatment Outcome | 4 | 2020 | 9692 | 0.090 |
Why?
| Rats | 3 | 2015 | 5426 | 0.090 |
Why?
| Sarcolemma | 2 | 2020 | 31 | 0.090 |
Why?
| Waist-Hip Ratio | 2 | 2009 | 31 | 0.090 |
Why?
| Age of Onset | 2 | 2009 | 479 | 0.090 |
Why?
| Anticholesteremic Agents | 1 | 2011 | 136 | 0.090 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1003 | 0.080 |
Why?
| Cytosol | 2 | 2020 | 229 | 0.080 |
Why?
| Puberty | 1 | 2010 | 149 | 0.080 |
Why?
| Leptin | 1 | 2010 | 233 | 0.080 |
Why?
| Alleles | 3 | 2018 | 852 | 0.080 |
Why?
| Radiography | 1 | 2011 | 888 | 0.080 |
Why?
| Infant, Newborn | 3 | 2021 | 5430 | 0.080 |
Why?
| Algorithms | 1 | 2015 | 1593 | 0.080 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 8 | 0.080 |
Why?
| Cystatins | 1 | 2007 | 7 | 0.080 |
Why?
| Mass Screening | 2 | 2013 | 1095 | 0.080 |
Why?
| Mice | 7 | 2022 | 15888 | 0.080 |
Why?
| Fatty Acids | 1 | 2010 | 410 | 0.080 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 985 | 0.080 |
Why?
| Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 209 | 0.080 |
Why?
| Contraceptive Agents, Female | 1 | 2008 | 65 | 0.080 |
Why?
| Antidepressive Agents | 1 | 2009 | 194 | 0.080 |
Why?
| Life Style | 1 | 2009 | 436 | 0.080 |
Why?
| Endoplasmic Reticulum | 2 | 2020 | 250 | 0.070 |
Why?
| Electrocardiography | 1 | 2010 | 620 | 0.070 |
Why?
| Sensitivity and Specificity | 3 | 2022 | 1855 | 0.070 |
Why?
| Extracellular Matrix | 1 | 2010 | 461 | 0.070 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 83 | 0.070 |
Why?
| Apolipoproteins A | 1 | 2006 | 18 | 0.070 |
Why?
| Gene Frequency | 3 | 2018 | 522 | 0.070 |
Why?
| Fatty Acids, Nonesterified | 2 | 2021 | 173 | 0.070 |
Why?
| Reference Values | 4 | 2010 | 789 | 0.070 |
Why?
| Interleukin-6 | 1 | 2010 | 702 | 0.070 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 228 | 0.070 |
Why?
| Registries | 3 | 2020 | 2020 | 0.070 |
Why?
| Receptors, Interleukin-2 | 1 | 2005 | 73 | 0.070 |
Why?
| Hydrogen-Ion Concentration | 2 | 2018 | 547 | 0.070 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 410 | 0.070 |
Why?
| Antihypertensive Agents | 2 | 2007 | 465 | 0.060 |
Why?
| Radiography, Abdominal | 1 | 2004 | 33 | 0.060 |
Why?
| Glucose | 2 | 2021 | 968 | 0.060 |
Why?
| Alcohol Drinking | 1 | 2009 | 668 | 0.060 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 1213 | 0.060 |
Why?
| Mice, Inbred NOD | 2 | 2015 | 588 | 0.060 |
Why?
| Odds Ratio | 3 | 2011 | 1043 | 0.060 |
Why?
| Infant | 2 | 2017 | 8523 | 0.060 |
Why?
| Stroke | 1 | 2012 | 1090 | 0.060 |
Why?
| Carotid Intima-Media Thickness | 1 | 2023 | 68 | 0.060 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 373 | 0.060 |
Why?
| Cathepsin D | 1 | 2022 | 13 | 0.050 |
Why?
| Exercise Tolerance | 1 | 2024 | 245 | 0.050 |
Why?
| Lung Neoplasms | 1 | 2015 | 2216 | 0.050 |
Why?
| Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.050 |
Why?
| Ketone Bodies | 1 | 2021 | 17 | 0.050 |
Why?
| 3-Hydroxybutyric Acid | 1 | 2021 | 15 | 0.050 |
Why?
| Lipase | 1 | 2002 | 70 | 0.050 |
Why?
| Smoking | 1 | 2009 | 1556 | 0.050 |
Why?
| Breath Tests | 1 | 2021 | 87 | 0.050 |
Why?
| Glycerol | 2 | 2012 | 90 | 0.050 |
Why?
| Ketones | 1 | 2021 | 45 | 0.050 |
Why?
| Technology | 1 | 2021 | 88 | 0.050 |
Why?
| Behavior Therapy | 1 | 2023 | 249 | 0.050 |
Why?
| Diabetes, Gestational | 1 | 2005 | 285 | 0.050 |
Why?
| Insulin Glargine | 1 | 2020 | 70 | 0.050 |
Why?
| Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| Phospholipids | 1 | 2021 | 211 | 0.040 |
Why?
| Mitochondria, Muscle | 1 | 2020 | 98 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2022 | 423 | 0.040 |
Why?
| Physical Endurance | 1 | 2020 | 234 | 0.040 |
Why?
| Aryldialkylphosphatase | 1 | 2019 | 20 | 0.040 |
Why?
| beta 2-Microglobulin | 1 | 2018 | 48 | 0.040 |
Why?
| Lipocalin-2 | 1 | 2018 | 65 | 0.040 |
Why?
| Insulin Aspart | 1 | 2018 | 26 | 0.040 |
Why?
| Microscopy, Polarization | 1 | 2018 | 33 | 0.040 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 35 | 0.040 |
Why?
| Retinal Artery | 1 | 2017 | 15 | 0.040 |
Why?
| Cytokines | 2 | 2017 | 1928 | 0.040 |
Why?
| Retinal Vein | 1 | 2017 | 13 | 0.040 |
Why?
| Fundus Oculi | 1 | 2017 | 41 | 0.040 |
Why?
| Postmenopause | 1 | 2020 | 307 | 0.040 |
Why?
| Injections | 1 | 2018 | 171 | 0.040 |
Why?
| Osmolar Concentration | 1 | 2018 | 185 | 0.040 |
Why?
| Pelvic Bones | 1 | 2020 | 120 | 0.040 |
Why?
| Canada | 1 | 2018 | 355 | 0.040 |
Why?
| Longevity | 1 | 2018 | 156 | 0.040 |
Why?
| Health Behavior | 1 | 2023 | 731 | 0.040 |
Why?
| Cell Nucleus | 1 | 2020 | 598 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2002 | 1188 | 0.040 |
Why?
| Athletes | 1 | 2020 | 355 | 0.040 |
Why?
| Vascular Resistance | 1 | 2018 | 374 | 0.040 |
Why?
| Photography | 1 | 2017 | 96 | 0.040 |
Why?
| Support Vector Machine | 1 | 2017 | 37 | 0.040 |
Why?
| Regional Blood Flow | 1 | 2018 | 427 | 0.040 |
Why?
| Feeding and Eating Disorders | 1 | 2018 | 127 | 0.040 |
Why?
| Blood Banks | 1 | 2016 | 43 | 0.040 |
Why?
| Administration, Inhalation | 1 | 2018 | 664 | 0.040 |
Why?
| Organ Size | 1 | 2017 | 474 | 0.040 |
Why?
| Health Personnel | 1 | 2022 | 603 | 0.040 |
Why?
| Area Under Curve | 1 | 2017 | 303 | 0.040 |
Why?
| Genetic Predisposition to Disease | 2 | 2018 | 2359 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2018 | 312 | 0.030 |
Why?
| Autophagy-Related Proteins | 1 | 2015 | 48 | 0.030 |
Why?
| Lipid Peroxidation | 1 | 2015 | 151 | 0.030 |
Why?
| Lipoproteins, LDL | 1 | 2015 | 138 | 0.030 |
Why?
| Acute Disease | 1 | 2017 | 984 | 0.030 |
Why?
| Kidney Tubules | 1 | 2015 | 128 | 0.030 |
Why?
| Blood Pressure Determination | 1 | 2015 | 135 | 0.030 |
Why?
| Sequence Homology, Amino Acid | 1 | 2015 | 376 | 0.030 |
Why?
| HLA-DQ Antigens | 1 | 2015 | 178 | 0.030 |
Why?
| Vasodilation | 1 | 2017 | 462 | 0.030 |
Why?
| Purines | 1 | 2015 | 166 | 0.030 |
Why?
| Phenotype | 2 | 2013 | 3070 | 0.030 |
Why?
| Biopsy | 1 | 2018 | 1090 | 0.030 |
Why?
| Antigen-Antibody Reactions | 1 | 2013 | 54 | 0.030 |
Why?
| Insulin-Secreting Cells | 1 | 2018 | 333 | 0.030 |
Why?
| Survival Analysis | 1 | 2017 | 1325 | 0.030 |
Why?
| Cause of Death | 1 | 2015 | 389 | 0.030 |
Why?
| Interleukin-10 | 1 | 2015 | 314 | 0.030 |
Why?
| Adenosine Triphosphate | 1 | 2015 | 456 | 0.030 |
Why?
| Mice, Knockout | 1 | 2019 | 2737 | 0.030 |
Why?
| Primary Prevention | 1 | 2015 | 212 | 0.030 |
Why?
| Mitochondria | 1 | 2018 | 809 | 0.030 |
Why?
| Abdominal Fat | 1 | 2012 | 48 | 0.030 |
Why?
| Molecular Weight | 1 | 2012 | 346 | 0.030 |
Why?
| Interferon-gamma | 1 | 2015 | 747 | 0.030 |
Why?
| Colesevelam Hydrochloride | 1 | 2011 | 7 | 0.030 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 336 | 0.020 |
Why?
| Vitamin D-Binding Protein | 1 | 2010 | 14 | 0.020 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2015 | 656 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 2015 | 2123 | 0.020 |
Why?
| Vascular Diseases | 1 | 2013 | 251 | 0.020 |
Why?
| Societies, Medical | 1 | 2015 | 741 | 0.020 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 57 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2013 | 1245 | 0.020 |
Why?
| Abdomen | 1 | 2010 | 117 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2015 | 2933 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2011 | 416 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2018 | 2127 | 0.020 |
Why?
| Biostatistics | 1 | 2009 | 18 | 0.020 |
Why?
| Finland | 1 | 2009 | 73 | 0.020 |
Why?
| Nutrition Surveys | 1 | 2011 | 240 | 0.020 |
Why?
| Cysts | 1 | 2010 | 94 | 0.020 |
Why?
| Hyperinsulinism | 1 | 2010 | 109 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2014 | 1423 | 0.020 |
Why?
| Calibration | 1 | 2009 | 140 | 0.020 |
Why?
| Proteins | 1 | 2015 | 953 | 0.020 |
Why?
| Europe | 1 | 2009 | 369 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2010 | 551 | 0.020 |
Why?
| Personality Inventory | 1 | 2009 | 137 | 0.020 |
Why?
| Spleen | 1 | 2010 | 543 | 0.020 |
Why?
| Environmental Monitoring | 1 | 2010 | 305 | 0.020 |
Why?
| Diabetic Neuropathies | 1 | 2009 | 100 | 0.020 |
Why?
| Health Surveys | 1 | 2009 | 468 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 12 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 22 | 0.020 |
Why?
| Lipid Metabolism | 1 | 2010 | 482 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 59 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 2013 | 1306 | 0.020 |
Why?
| Patient Compliance | 1 | 2011 | 561 | 0.020 |
Why?
| Body Composition | 1 | 2010 | 668 | 0.020 |
Why?
| Analysis of Variance | 1 | 2010 | 1329 | 0.020 |
Why?
| Ultrasonography | 1 | 2010 | 740 | 0.020 |
Why?
| Patient Selection | 1 | 2010 | 717 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2011 | 2501 | 0.020 |
Why?
| Amino Acid Substitution | 1 | 2006 | 278 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2015 | 3799 | 0.020 |
Why?
| Heart Ventricles | 1 | 2010 | 741 | 0.020 |
Why?
| Maternal Age | 1 | 2005 | 124 | 0.020 |
Why?
| Age Distribution | 1 | 2005 | 376 | 0.020 |
Why?
| Child, Preschool | 1 | 2017 | 9755 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 2011 | 5020 | 0.010 |
Why?
| Signal Transduction | 1 | 2015 | 4902 | 0.010 |
Why?
| Oxidative Stress | 1 | 2006 | 1204 | 0.010 |
Why?
| DNA | 1 | 2006 | 1401 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2010 | 3264 | 0.010 |
Why?
|
|
Snell-Bergeon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|